Market cap
$3.1bn
Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
These decreases will be partially offset by our increased investment in the development of casdatifan and advancement of our small-molecule immunology programs. The decrease in Total revenues for the six months ended June 30, 2026 was primarily driven by the cumulative catch-up from license and development services revenue of $143 million in 2025 due to Gilead's return of its license to the etrumadenant program, partially offset by: (i) an increase in access rights revenues recognized in the second quarter 2026 related to the expiration of Gilead's option rights; and (ii) increased revenues related to programs optioned under the Taiho Collaboration Agreement. …Arcus Biosciences, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05